Abstracts tagged "Biomarkers"

Abstract Number: 2371 • 2016 ACR/ARHP Annual Meeting
Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Féline Kroon¹, Ruth Wittoek², Wing-Yee Kwok¹, Klaus Bobacz³, Dirk Elewaut², Marta Favero⁴, Tom Huizinga⁵, Josef Smolen³, Bert Vander Cruyssen², Ron Wolterbeek⁶, Leonardo Punzi⁷, Gust Verbruggen², Margreet Kloppenburg⁸ and Roberta Ramonda⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology Unit,Department of Medicine–DIMED, University of Padova, Rheumatology Unit,University of Padova, Padova, Italy, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁸Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Erosive hand osteoarthritis (OA) is a hand OA subset with high disease burden, although effective therapies are still lacking and clinical trials are scarce.…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 482 • 2016 ACR/ARHP Annual Meeting
Comparison of Nonclinical Pharmacology, Pharmacodynamics and Efficacy Response of the Proposed Adalimumab Biosimilar GP2017 to Originator Adalimumab
Antonio Dasilva¹, Ulrich Kronthaler¹, Hans-Peter Hofmann², Vera Koppenburg¹, Melanie Baron³, Cornelius Fritsch⁴, Otmar Hainzl¹ and Andreas Seidl¹, ¹Sandoz Biopharmaceuticals, Holzkirchen, Germany, ²Pre-clinical, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ³Clinical Development, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ⁴Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Biosimilars are created to be essentially the same as their reference marketed biopharmaceuticals which have lost exclusivity, and they aim to offer more affordable…
Abstract Number: 1037 • 2016 ACR/ARHP Annual Meeting
Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Monika Hansson¹, Linda Mathsson-Alm², Anthony Marotta³ and Sascha Swiniarski⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Thermo Fisher Scientific, Uppsala, Sweden, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴ImmunoDiagnostics Division Thermo Fisher Scientific, Phadia GmbH, Freiburg, Germany
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) coupled with an effective treatment strategy is a key imperative in the effective management of disease. Anti-citrullinated peptide…
Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background
Nelly Ziade¹, Fouad Fayad¹, Iyad Mallak², Georges Merheb³, Torsten Witte⁴ and Xenofon Baraliakos⁵, ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁵Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁸ and Anca D. Askanase⁹, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Exagen Diagnostics, Inc., Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁸Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁹Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 2640 • 2016 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?
Masao Sato¹, Masao Takemura², Yasuko Yamamoto³ and Kuniaki Saito⁴, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Advanced Diagnostic System Research Laboratory, Fujita Health University, Toyoake, Japan, ³Disease Control and Prevention, Fujita Health University, Toyoake, Japan, ⁴Disease Control and Prevention, Fjita Health University, Aichi, Japan
Background/Purpose: GP88 (progranulin; PGRN) is a glycoprotein with a molecular weight of approximately 88,000 Da and is thought to play an important role in…
Abstract Number: 3180 • 2016 ACR/ARHP Annual Meeting
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Sarah M Moran¹, Michelle Ryan¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Jean Dunne⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁴, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹⁴, Steven R. Ytterberg¹⁵, Lina Zgaga¹⁶, Peter A. Merkel¹⁷, Mark A. Little¹⁸ and the Vasculitis Clinical Research Consortium, ¹Clinical Medicine, Trinity Health Kidney Centre, Dublin, Ireland, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Immunology Department, St James's Hospital, Dublin, Ireland, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, The University of Pennsylvania, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples from patients with…
Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Julio Ramírez¹, Andrea Cuervo², Jose Antonio Narváez³, Virginia Ruiz-Esquide², Javier Hernández-Gañán³, Raquel Celis⁴, Jose Inciarte-Mundo², M. Victoria Hernández², Jose L. Pablos⁵, Raimon Sanmarti² and Juan D. Cañete², ¹Rheumatology, Hospital Clínic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Radiology, Hospital Bellvitge, Barcelona, Spain, ⁴Rheumatology, Arthritis Unit, Barcelona, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…
Abstract Number: 1046 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures
Lars Rogge¹, Silvia Menegatti², Eleonora Latis¹, Elena Mascia¹, Hanane Yahia¹, Claire Leloup¹, Anna Molto³, Corinne Miceli-Richard⁴, Maxime Dougados^5,6 and Elisabetta Bianchi¹, ¹Immunology, Institut Pasteur, Paris, France, ²Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ³Hopital Cochin, Paris Descartes University, Paris, France, ⁴Rheumatology, Hôpital Cochin, Paris, France, ⁵Paris Descartes University, Paris, France, ⁶Service de Rhumatologie B, Hopital Cochin, Paris, France
Background/Purpose: The introduction of anti-TNF therapy has proven effective to reduce inflammation and clinical symptoms in several chronic inflammatory diseases. However, TNF-blockers are effective only…
Abstract Number: 1677 • 2016 ACR/ARHP Annual Meeting
Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Andreas Kerschbaumer^1,2, Karl Fenzl², Michael Weber³, Johannes Resch⁴, Martin Kasper⁴, Daniel Aletaha⁵ and Ludwig Erlacher^4,6, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Institute for Autoimmune Diseases and Rheumatology, Karl Landsteiner Institute, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴2nd Medical Department, Department for Rheumatology, Osteology and Geriatric medicine, Sozialmedizinisches Zentrum Sued, Vienna, Austria, ⁵Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ⁶Karl Landsteiner Institute, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in a subgroup of patients suffering from psoriasis. Assessment of PsA disease activity currently mainly…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].